drugset

drugset / Trial / NCT02254005

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

NCT02254005 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

Timeline

Start: 2002-10-01
Primary completion: 2004-12-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	bivatuzumab mertansine	Unknown	—	Intravenous

Indications